MX2021003869A - Composiciones útiles para tratar la gangliosidosis gm1. - Google Patents
Composiciones útiles para tratar la gangliosidosis gm1.Info
- Publication number
- MX2021003869A MX2021003869A MX2021003869A MX2021003869A MX2021003869A MX 2021003869 A MX2021003869 A MX 2021003869A MX 2021003869 A MX2021003869 A MX 2021003869A MX 2021003869 A MX2021003869 A MX 2021003869A MX 2021003869 A MX2021003869 A MX 2021003869A
- Authority
- MX
- Mexico
- Prior art keywords
- gbl1
- gangliosidosis
- reduction
- gene
- treating
- Prior art date
Links
- 201000008892 GM1 Gangliosidosis Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 abstract 1
- 108010005774 beta-Galactosidase Proteins 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000002132 lysosomal effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona un virus adenoasociado recombinante (rAAV) que comprende una cápside de AAVhu68 y un genoma del vector que comprende un gen de beta-galactosidasa lisosomal (por ejemplo, gen de galactosidasa beta 1, GBL1) (es decir, rAAVhu68.GBL1); también se proporcionó una composición que contiene una cantidad eficaz de rAAVhu68.GBL1 para mejorar los síntomas de la gangliosidosis GM1, que incluyen, por ejemplo, expectativa de vida promedio aumentada, menor necesidad de sonda de alimentación, reducción de la cantidad y frecuencia de convulsiones, reducción de la progresión hacia deterioro neurocognitivo y/o mejora del desarrollo neurocognitivo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862739811P | 2018-10-01 | 2018-10-01 | |
US201962835178P | 2019-04-17 | 2019-04-17 | |
PCT/US2019/053797 WO2020072354A1 (en) | 2018-10-01 | 2019-09-30 | Compositions useful for treating gm1 gangliosidosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003869A true MX2021003869A (es) | 2021-09-08 |
Family
ID=69165478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021003869A MX2021003869A (es) | 2018-10-01 | 2019-09-30 | Composiciones útiles para tratar la gangliosidosis gm1. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230040603A1 (es) |
EP (1) | EP3860659A1 (es) |
JP (1) | JP2022512589A (es) |
KR (1) | KR20210071017A (es) |
CN (1) | CN113438954A (es) |
AU (1) | AU2019351815A1 (es) |
BR (1) | BR112021006060A2 (es) |
CA (1) | CA3114175A1 (es) |
CL (1) | CL2021000798A1 (es) |
CO (1) | CO2021005443A2 (es) |
IL (1) | IL281923A (es) |
MX (1) | MX2021003869A (es) |
PE (1) | PE20211596A1 (es) |
SG (1) | SG11202102942VA (es) |
WO (1) | WO2020072354A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021155337A1 (en) * | 2020-02-02 | 2021-08-05 | The Trustees Of The University Of Pennsylvania | Compositions useful for treating gm1 gangliosidosis |
CN116926047A (zh) * | 2022-03-31 | 2023-10-24 | 北京锦篮基因科技有限公司 | 功能性β-半乳糖苷酶变体、AAV介导的人β-半乳糖苷酶表达载体及其用途 |
WO2024080569A1 (en) * | 2022-10-12 | 2024-04-18 | Novel Pharma Inc. | Pharmaceutical composition for treating, preventing or ameliorating gm1 gangliosidosis or morquio syndrome b and administration method thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
ES2224375T3 (es) | 1997-04-14 | 2005-03-01 | Cell Genesys, Inc. | Metodos para aumentar la eficacia del producto de aav recombinante. |
EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
JP2002538770A (ja) | 1998-11-10 | 2002-11-19 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ウイルスベクターとその製造及び投与の方法 |
AU6814901A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
DK1310571T3 (da) | 2001-11-13 | 2006-06-19 | Univ Pennsylvania | Fremgangsmåde til identifikation af ukendte adeno-associerede virussekvenser (AAV-sekvenser) og et kit til fremgangsmåden |
WO2003104413A2 (en) | 2002-06-05 | 2003-12-18 | University Of Florida | Production of pseudotyped recombinant aav virions |
US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
EP2434420A3 (en) | 2003-08-01 | 2012-07-25 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
ES2411479T3 (es) | 2003-09-30 | 2013-07-05 | The Trustees Of The University Of Pennsylvania | Clados de virus adeno-asociados (AAV), secuencias, vectores que los contienen, y usos de los mismos |
EP3085389A1 (en) | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
JP5922095B2 (ja) | 2010-03-29 | 2016-05-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 薬理学的に誘導される導入遺伝子アブレーション系 |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
BR112017005892A2 (pt) | 2014-09-24 | 2017-12-12 | Hope City | variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma |
EP3285788A4 (en) * | 2015-04-23 | 2018-12-05 | University of Massachusetts | Modulation of aav vector transgene expression |
WO2017160360A2 (en) | 2015-12-11 | 2017-09-21 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav9 |
SG10201912976WA (en) * | 2017-02-28 | 2020-02-27 | Univ Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
-
2019
- 2019-09-30 MX MX2021003869A patent/MX2021003869A/es unknown
- 2019-09-30 JP JP2021518190A patent/JP2022512589A/ja active Pending
- 2019-09-30 WO PCT/US2019/053797 patent/WO2020072354A1/en active Application Filing
- 2019-09-30 US US17/281,378 patent/US20230040603A1/en active Pending
- 2019-09-30 KR KR1020217012705A patent/KR20210071017A/ko unknown
- 2019-09-30 PE PE2021000431A patent/PE20211596A1/es unknown
- 2019-09-30 EP EP19836625.4A patent/EP3860659A1/en active Pending
- 2019-09-30 CA CA3114175A patent/CA3114175A1/en active Pending
- 2019-09-30 AU AU2019351815A patent/AU2019351815A1/en active Pending
- 2019-09-30 SG SG11202102942VA patent/SG11202102942VA/en unknown
- 2019-09-30 BR BR112021006060-0A patent/BR112021006060A2/pt unknown
- 2019-09-30 CN CN201980079543.8A patent/CN113438954A/zh active Pending
-
2021
- 2021-03-29 CL CL2021000798A patent/CL2021000798A1/es unknown
- 2021-03-31 IL IL281923A patent/IL281923A/en unknown
- 2021-04-27 CO CONC2021/0005443A patent/CO2021005443A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20211596A1 (es) | 2021-08-18 |
BR112021006060A2 (pt) | 2021-07-20 |
JP2022512589A (ja) | 2022-02-07 |
WO2020072354A1 (en) | 2020-04-09 |
CA3114175A1 (en) | 2020-04-09 |
EP3860659A1 (en) | 2021-08-11 |
SG11202102942VA (en) | 2021-04-29 |
CO2021005443A2 (es) | 2021-04-30 |
IL281923A (en) | 2021-05-31 |
US20230040603A1 (en) | 2023-02-09 |
KR20210071017A (ko) | 2021-06-15 |
CL2021000798A1 (es) | 2021-08-27 |
AU2019351815A1 (en) | 2021-05-06 |
CN113438954A (zh) | 2021-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021003869A (es) | Composiciones útiles para tratar la gangliosidosis gm1. | |
PH12021551341A1 (en) | Compositions for drg-specific reduction of transgene expression | |
Iwakiri et al. | Epstein–Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines | |
RU2017142006A (ru) | Векторы на основе аденоассоциированных вирусов для лечения мукополисахаридозов | |
Yang et al. | Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model | |
WO2022040527A3 (en) | Adeno-associated virus compositions having preferred expression levels | |
MX2021013266A (es) | Nuevas capsides de aav y composiciones que las contienen. | |
MX2021012311A (es) | Variantes de capsides de aav para liberacion intravitrea. | |
BR112022011916A2 (pt) | Composições para tratar a ataxia de friedreich | |
US11807868B2 (en) | Adeno-associated variants, formulations and methods for pulmonary delivery | |
MX2023001863A (es) | Nuevas cápsides de aav y composiciones que las contienen. | |
MX2022011777A (es) | Itrs libres de cpg para la terapia genica aav. | |
Yin et al. | AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo | |
MX2021012682A (es) | Metodos y composiciones para la expresion del transgen. | |
MX2020003042A (es) | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. | |
EA202190951A1 (ru) | Композиции, применяемые для лечения gm1-ганглиозидоза | |
MX2023001419A (es) | Vector viral adenoasociado para la expresion de glut1 y usos de este. | |
MX2022009252A (es) | Proteinas de la capside de virus adeno-asociados modificadas para la terapia genica ocular y metodos de uso de las mismas. | |
AR116560A1 (es) | Composiciones útiles para el tratamiento de la gangliosidosis gm1 | |
Guo et al. | Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models | |
JP7142643B2 (ja) | Hdac阻害剤またはrepタンパク質を伴う細胞培養方法 | |
MX2023006694A (es) | Tratamiento de la enfermedad de danon. | |
Teschendorf et al. | Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells | |
Nagai et al. | Modulation of Treg function improves adenovirus vector-mediated gene expression in the airway | |
EP2871240B1 (en) | Recombinant adenovirus for simultaneously expressing pig interferon alpha and pig interferon gamma |